Guideline:

Vitamin A supplementation in infants and children 6–59 months of age
# Contents

Acknowledgements  iv  
Financial support  iv  
Summary  1  
Scope and purpose  2  
Background  2  
Summary of evidence  3  
Recommendation  4  
Remarks  5  
Dissemination, adaptation and implementation  6  

*Dissemination*

*Adaptation and implementation*

*Monitoring and evaluation of guideline implementation*

Implications for future research  8  
Guideline development process  8  

*Advisory groups*

*Scope of the guideline, evidence appraisal and decision-making*

Management of conflicts of interest  10  
Plans for updating the guideline  11  
References  12  

Annex 1  GRADE “Summary of findings” table  14  
Annex 2  Members of the WHO/UNICEF Steering Committee  
for guidelines on vitamin A supplementation  16  
Annex 3  Members of the Vitamin A Supplementation Guideline Group,  
WHO Secretariat and external resource experts  17  
Annex 4  Members of the External Experts and Stakeholders Panel  20  
Annex 5  Questions in Population, Intervention, Control,  
Outcomes (PICO) format  23  
Annex 6  Summary of considerations for determining  
the strength of the recommendation  24
Acknowledgements

This guideline was coordinated by Dr Lisa Rogers under the supervision of Dr Juan Pablo Peña-Rosas, with technical input from Dr Rajiv Bahl, Dr Luz Maria de Regil, Ms Tracey Goodman and Dr Jose Martines. Thanks are due to Dr Regina Kulier and the staff at the Guidelines Review Committee Secretariat for their support throughout the process. Thanks are also due to Dr Davina Gherisi for her technical advice and assistance in the preparation of the technical consultations for this guideline and Mr Issa T. Matta and Mrs Chantal Streijffert Garon from the World Health Organization (WHO) Office of the Legal Counsel for their support in the management of conflicts of interest procedures. Ms Grace Rob and Mrs Paule Pillard from the Micronutrients Unit, Department of Nutrition for Health and Development, provided logistic support.

WHO gratefully acknowledges the technical input of the members of the WHO/United Nations Children's Fund (UNICEF) Steering Committee, the Vitamin A Supplementation Guideline Group and the External Experts and Stakeholders Panel. WHO is also grateful to the Cochrane Editorial Unit for its support in coordinating the update of the systematic reviews used to inform this guideline and the evidence summary of findings.

Financial support

WHO thanks the Government of Luxembourg for providing financial support for this work.
Vitamin A deficiency affects about 19 million pregnant women and 190 million preschool-age children, mostly from the World Health Organization (WHO) regions of Africa and South-East Asia. Infants and children have increased vitamin A requirements to support rapid growth and to help them combat infections. Member States have requested guidance from WHO on the effects and safety of vitamin A supplementation in infants and children 6–59 months of age as a public health strategy in support of their efforts to achieve the Millennium Development Goals.

WHO has developed the present evidence-informed recommendation using the procedures outlined in the WHO handbook for guideline development. The steps in this process included: (i) identification of priority questions and outcomes; (ii) retrieval of the evidence; (iii) assessment and synthesis of the evidence; (iv) formulation of recommendations, including future research priorities; and (v) planning for dissemination, implementation, impact evaluation and updating of the guideline. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was followed to prepare evidence profiles related to preselected topics, based on up-to-date systematic reviews. An international, multidisciplinary group of experts participated in two WHO technical consultations, held in Geneva, Switzerland, on 19–20 October 2009 and 16–18 March 2011, to review and discuss the evidence and draft recommendation, and to vote on the strength of the recommendation, taking into consideration: (i) desirable and undesirable effects of this intervention; (ii) the quality of the available evidence; (iii) values and preferences related to the intervention in different settings; and (iv) the cost of options available to health-care workers in different settings. All guideline group members completed a Declaration of Interests Form before each meeting. An External Experts and Stakeholders Panel was involved throughout the process.

In settings where vitamin A deficiency is a public health problem, vitamin A supplementation is recommended in infants and children 6–59 months of age as a public health intervention to reduce child morbidity and mortality (strong recommendation). The quality of the available evidence for all-cause mortality was high, whereas for all other critical outcomes it was moderate to very low. The quality of the available evidence for outcomes in human immunodeficiency virus (HIV)-positive children was moderate for all-cause mortality.
Scope and purpose

This guideline provides global, evidence-informed recommendations on the use of vitamin A supplements in infants and children 6–59 months of age for the reduction of morbidity and mortality.

The guideline will help Member States and their partners in their efforts to make informed decisions on the appropriate nutrition actions to achieve the Millennium Development Goals, in particular, reduction in child mortality (MDG 4). The guideline is intended for a wide audience including policy-makers, their expert advisers, and technical and programme staff in organizations involved in the design, implementation and scaling-up of nutrition actions for public health.

This document presents the key recommendation and a summary of the supporting evidence. Further details of the evidence base are provided in Annex 1 and other documents listed in the references.

Background

Vitamin A deficiency is a major public health problem affecting an estimated 190 million preschool-age children, mostly from the World Health Organization (WHO) regions of Africa and South-East Asia (1). Infants and children have increased vitamin A requirements to promote rapid growth and to help combat infections. Inadequate intakes of vitamin A at this age could lead to vitamin A deficiency, which, when severe, may cause visual impairment (night blindness) or increase the risk of illness and mortality from childhood infections such as measles and those causing diarrhoea (2).

The combination of childhood underweight, micronutrient deficiencies (iron, vitamin A and zinc) and suboptimal breastfeeding is responsible for 7% of deaths and 10% of the total disease burden (3). Vitamin A deficiency alone is responsible for almost 6% of child deaths under the age of 5 years in Africa and 8% in South-East Asia (3). Vitamin A supplementation in children 6–59 months of age living in developing countries is associated with a reduced risk of all-cause mortality and a reduced incidence of diarrhoea (4). The mechanisms by which vitamin A reduces mortality are not fully understood, and it is not clear whether its action is mediated through the correction of underlying deficiencies or through adjuvant therapeutic effects. Vitamin A supplementation may improve gut integrity and therefore decrease the severity of some diarrhoeal episodes (5). The role of vitamin A in innate and adaptive immunity may also include reducing susceptibility to and/or severity of other infections (6, 7).

Many countries have integrated strategies to deliver vitamin A supplements to infants and children in their national health policies (8, 9). The delivery of vitamin A has been integrated into routine health services, for example through the establishment of biannual “special days”, when vitamin A supplementation is combined with other child survival interventions such as deworming or nutrition education. Vitamin A supplements are also commonly distributed as part of the Expanded Programme on Immunization (especially at 9 months, alongside measles vaccination). In 2009, about 77% of preschool children in more than 103 priority countries received two doses of vitamin A supplements (10).
Provision of high doses of vitamin A every 6 months until the age of 5 years was based on the principle that a single, large dose of vitamin A is well absorbed and stored in the liver, and then mobilized, as needed, over an extended period of time (11). A dose of 100 000 International Units (IU) in infants 6–11 months of age and 200 000 IU in children 12–59 months of age is considered to provide adequate protection for 4–6 months, with the exact interval depending on the vitamin A content of the diet and the rate of utilization by the body (8, 12).

In most children 6–59 months of age, a dose of 100 000–200 000 IU of vitamin A is well tolerated, although side-effects such as headache, nausea or vomiting, and diarrhoea have been reported in 3–7% of these children (13). However, these symptoms are transient, with the large majority starting and disappearing within 24 hours of dosing. There are no known deaths attributed solely to vitamin A toxicity due to overconsumption of vitamin A (13).

On a per-child basis, vitamin A supplementation is considered a low-cost intervention. Most of the vitamin A used during supplementation campaigns is supplied in gelatin capsules which cost approximately US$ 0.02 each (14), with an estimated cost of US$ 1–2 for delivery per child per year (15). The total cost of supplementation per death averted is estimated at US$ 200–250 (16, 17).

Two existing Cochrane systematic reviews assessing the effects and safety of vitamin A supplementation in children 6–59 months of age were updated for this guideline (4, 18). One review evaluated the effectiveness of vitamin A supplements in the prevention of morbidity and mortality in children 6–59 months of age (4). It showed that giving vitamin A supplements to children reduces the rates of mortality and some diseases. A meta-analysis of 17 trials (11 in Asia, 5 in Africa and 1 in Latin America) for all-cause mortality indicated that vitamin A reduces the overall risk of death by 24% (risk ratio (RR) 0.76; 95% confidence interval (CI) 0.69–0.83). When an unpublished cluster-randomized trial involving one million children in north India (the DEVTA trial) was considered, vitamin A supplementation reduced the effect size of all-cause mortality from 24% to 12% (RR 0.88; 95% CI 0.84–0.94). Due to limited availability of information on the DEVTA trial the quality of this trial could not be assessed.

Seven trials indicated that vitamin A supplementation significantly reduces diarrhoea-related mortality (RR 0.72; 95% CI 0.57–0.91), although mortality specifically due to measles (five trials: RR 0.80; 95% CI 0.51–1.24) or respiratory disease (seven trials: RR 0.78; 95% CI 0.54–1.14) was not reduced. The occurrence of new episodes of diarrhoea decreased (13 trials: RR 0.85; 95% CI 0.82–0.87). There was no significant effect on the incidence of respiratory disease (nine trials: RR 1.14; 95% CI 0.95–1.37), or hospitalizations due to diarrhoea or pneumonia.

There was a significantly increased risk of vomiting within the first 48 hours of supplementation with 100 000–200 000 IU of vitamin A (three trials: RR 2.75; 95% CI 1.81–4.19). Only one study reported data on bulging fontanelles as most studies
included children over 1 year of age and thus would not have assessed this side-effect. There was no significant effect of vitamin A supplementation when the data were stratified by national child mortality rates (data from countries with low versus high child mortality rates) (4). It was not possible to perform subgroup analyses for dose and frequency of supplementation as the analyses were underpowered and any effects would have been attributed to chance.

The second review assessed whether micronutrient supplements, including vitamin A, are safe and effective in reducing morbidity and mortality in adults and children with human immunodeficiency virus (HIV) infection (18). It included five trials on vitamin A supplementation in children with a total of 1120 participants; only three trials (262 participants, all in Africa) contributed data on all-cause mortality. The data suggest that vitamin A reduces the overall risk of death (RR 0.55; 95% CI 0.37–0.82).

The overall quality of the evidence for all-cause mortality was high, whereas it was moderate to very low for the remaining critical outcomes (Annex 1). The quality of the available evidence for outcomes in HIV-positive children was moderate for all-cause mortality.

The effect of vitamin A supplementation on antibody response to measles vaccination has recently been evaluated in an additional review (19). A meta-analysis of seven trials indicated that vitamin A supplementation at 6 or 9 months of age did not affect the measles vaccine response (seroconversion rates). No study has prospectively assessed the impact of co-administration of vitamin A and measles vaccine on child mortality.

**Recommendation**

High-dose vitamin A supplementation is recommended in infants and children 6–59 months of age in settings where vitamin A deficiency is a public health problem\(^1\) (**strong recommendation**\(^2\)).

A suggested vitamin A supplementation scheme for infants and children 6–59 months of age is presented in Table 1.

---

\(^1\) Determination of vitamin A deficiency as a public health problem involves estimating the prevalence of deficiency in a population by using specific biochemical and clinical indicators of vitamin A status. Classification of countries based on the most recent estimates is available in reference (1).

\(^2\) A strong recommendation is one for which the guideline development group is confident that the desirable effects of adherence outweigh the undesirable effects. The recommendation can be either in favour of or against an intervention. Implications of a strong recommendation for patients are that most people in their situation would want the recommended course of action and only a small proportion would not. Implications for clinicians are that most patients should receive the recommended course of action, and that adherence to this recommendation is a reasonable measure of good-quality care. With regard to policy-makers, a strong recommendation means that it can be adapted as a policy in most situations.
Vitamin A supplementation in infants and children 6–59 months of age

**Target group**
- Infants 6–11 months of age (including HIV+)
- Children 12–59 months of age (including HIV+)

**Dose**
- 100 000 IU (30 mg RE) vitamin A
- 200 000 IU (60 mg RE) vitamin A

**Frequency**
- Once
- Every 4–6 months

**Route of administration**
- Oral liquid, oil-based preparation of retinyl palmitate or retinyl acetate

**Settings**
- Populations where the prevalence of night blindness is 1% or higher in children 24–59 months of age or where the prevalence of vitamin A deficiency (serum retinol 0.70 µmol/l or lower) is 20% or higher in infants and children 6–59 months of age

IU, international units; RE, retinol equivalent.

* An oil-based vitamin A solution can be delivered using soft gelatin capsules, as a single-dose dispenser or a graduated spoon (20). Consensus among manufacturers to use consistent colour coding for the different doses in soft gelatin capsules, namely red for the 200 000 IU capsules and blue for the 100 000 IU capsules, has led to much-improved training and operational efficiencies in the field.

**Remarks**

- This guideline replaces previous recommendations on vitamin A supplementation for the prevention of vitamin A deficiency, xerophthalmia and nutritional blindness in infants and children 6–59 months of age (8).

- The above recommendation can also be applied in populations where infants and children may be infected with HIV.

- The magnitude of the effect may differ across settings and populations, possibly due to the extent of vitamin A deficiency or the availability of other nutrients (e.g. dietary intake of vitamin A will differ across locations and the effects of supplementation may be smaller in places with greater access to vitamin A-rich foods or with regular consumption of vitamin A-fortified foods).

- This intervention should be used along with other strategies to improve vitamin A intakes, such as dietary diversification (21) and food fortification (22).
Dissemination, adaptation and implementation

The current guideline will be disseminated through electronic media such as slide presentations, CD-ROMs and the World Wide Web, either through the WHO Micronutrients and United Nations Standing Committee on Nutrition (SCN) mailing lists or the WHO nutrition web site. Currently, the WHO Department of Nutrition for Health and Development is developing the WHO electronic Library of Evidence for Nutrition Actions (eLENA). This library aims to compile and display WHO guidelines related to nutrition along with complementary documents such as systematic reviews and other evidence informing the guidelines, biological and behavioural rationales, and additional resources produced by Member States and global partners.

Adaptation and implementation

As this is a global guideline, it should be adapted to the context of each Member State. Prior to implementation, a vitamin A supplementation programme should include well-defined objectives that take into account available resources, existing

- Adverse effects within 48 hours of receiving supplements containing 100,000–200,000 IU vitamin A are usually mild and transient, with no long-term consequences. Adverse effects may include bulging of open fontanelles in younger infants, and nausea and/or vomiting and headache in older children with closed fontanelles.

- Vitamin A supplements should be delivered to children 6–59 months of age twice yearly, during health system contacts. This should be marked on the child health card, or integrated into other public health programmes aimed at improving child survival, such as polio or measles national immunization days, or biannual child health days delivering a package of interventions such as deworming, distribution of insecticide-treated mosquito nets and immunizations.

- A quality assurance process should be established to guarantee that supplements are manufactured, packaged and stored in a controlled and uncontaminated environment (23).

- When determining the vitamin A status of a population, guidelines on indicators for assessing vitamin A deficiency should be referred to (24, 25).

- Recommendations for the treatment of xerophthalmia and the use of vitamin A supplements during episodes of measles are not covered in this guideline. Existing guidelines on the treatment of xerophthalmia and measles in infants and children 6–59 months of age should be referred to in these cases (8, 26).
policies, appropriate delivery and communication channels, and potential stakeholders and suppliers. Ideally, interventions should be implemented as part of an integrated strategy that includes control of nutritional deficiencies; the programme should begin as a pilot and scaled up as the evidence grows and resources allow.

To ensure that WHO global guidelines and other evidence-informed recommendations for micronutrient interventions are better implemented in low- and middle-income countries, the Department of Nutrition for Health and Development works with the WHO Evidence-Informed Policy Network (EVIPNet) programme. EVIPNet promotes partnerships at country level between policy-makers, researchers and civil society to facilitate policy development and implementation through use of the best available evidence.

Monitoring and evaluation of guideline implementation

A plan for monitoring and evaluation with appropriate indicators is encouraged at all stages. The impact of this guideline can be evaluated within countries (i.e. monitoring and evaluation of the programmes implemented at scale) and across countries (i.e. the adoption and adaptation of the guideline globally). The WHO Department of Nutrition for Health and Development, Micronutrients Unit, jointly with the Centers for Disease Control and Prevention (CDC) International Micronutrient Malnutrition Prevention and Control (IMMPaCt) programme, and with input from international partners, has developed a generic logic model for micronutrient interventions in public health to depict these plausible relationships between inputs and expected MDGs by applying the micronutrient programmes evaluation theory (27). Member States can adjust the model and use it in combination with appropriate indicators for designing, implementing, monitoring and evaluating the successful scaling-up of nutrition actions.

For evaluation at the global level, the WHO Department of Nutrition for Health and Development is developing a centralized platform for sharing information on nutrition actions in public health practice implemented around the world. By sharing programme details, specific country adaptations and lessons learnt, this platform will provide examples of how the guidelines are being translated into nutrition actions. To be successful, this platform will need to be a collaborative effort, where the work of the entire international community can be shared, so countries worldwide can benefit as they attempt to implement nutrition actions.
Implications for future research

Discussion with the guideline group members and the External Experts and Stakeholders Panel highlighted the limited evidence in some areas, meriting further research on vitamin A supplementation in infants and children 6–59 months of age, in particular, in the following areas:

- effect of different doses of vitamin A on the critical outcomes of morbidity and mortality, and stratification of the data by sex, length of follow-up, vaccination status and subsequent vitamin A supplementation;
- the role of vitamin A supplementation in countries with high measles immunization rates and its effect on measles-related mortality;
- comparative analysis of the different delivery mechanisms of vitamin A (capsules versus droppers for delivery of supplemental vitamin A, food fortificants);
- identification of field-friendly clinical and biochemical indicators of vitamin A status and vitamin A stores;
- co-interventions that may interact with vitamin A, for example other nutrients (such as vitamin D) and vaccines (such as diphtheria, tetanus, polio).

Guideline development process

This guideline was developed in accordance with the WHO evidence-informed guideline development procedures, as outlined in the WHO handbook for guideline development (28).

Advisory groups

A WHO/United Nations Children’s Fund (UNICEF) Steering Committee for Guidelines on Vitamin A Supplementation was established in 2009 with representatives from the WHO departments of Child and Adolescent Health and Development; Immunizations, Vaccines and Biologicals; Making Pregnancy Safer; Nutrition for Health and Development; Reproductive Health and Research; and the Nutrition Section of UNICEF (Annex 2). The Steering Committee guided the development of this guideline and provided overall supervision of the guideline development process. Two additional groups were formed: an advisory guideline group and an External Experts and Stakeholders Panel.

The Vitamin A Supplementation Guideline Group included experts from various WHO expert advisory panels and those identified through open calls for specialists, taking into consideration a balanced gender mix, multiple disciplinary areas of expertise and representation from all WHO regions (Annex 3). Efforts were made to include content experts, methodologists, representatives of potential stakeholders (such as managers and other health professionals involved in the health-care process) and consumers. Representatives of commercial organizations may not be members of a WHO guideline group. The role of the guideline group was to advise WHO on the
choice of important outcomes for decision-making and the interpretation of the evidence.

The External Experts and Stakeholders Panel was consulted on the scope of the document, the questions addressed and the choice of important outcomes for decision-making, as well as with regard to review of the completed draft guideline (Annex 4). This was done through the WHO Micronutrients and SCN mailing lists, which together include over 5500 subscribers, and through the WHO nutrition website.

**Scope of the guideline, evidence appraisal and decision-making**

An initial set of questions (and the components of the questions) to be addressed in the guideline was the critical starting point for formulating the recommendation; the questions were drafted by technical staff at the Micronutrients Unit, Department of Nutrition for Health and Development, in collaboration with the Nutrition Section of UNICEF, based on policy and programme guidance needs of Member States and their partners. The population, intervention, control, outcomes (PICO) format was used (Annex 5). The questions were discussed and reviewed by the Steering Committee and feedback was received from 45 stakeholders.

The first guideline group meeting was held on 19–20 October 2009 in Geneva, Switzerland, to finalize the scope of the questions and rank the critical outcomes and populations of interest. The guideline group members discussed the relevance of each question and modified them as needed. They scored the relative importance of each outcome from 1 to 9 (7–9 indicated that the outcome was critical for a decision, 4–6 indicated that it was important and 1–3 indicated that it was not important). The final key question on vitamin A supplementation in infants and children 6–59 months of age, along with the outcomes that were identified as critical for decision-making, are listed in PICO format in Annex 5.

The Cochrane Collaboration was commissioned to search, review and generate systematic reviews, evidence profiles and the “Summary of findings” table (Annex 1). Two existing Cochrane reviews on vitamin A supplementation in children were updated, and the up-to-date Review Manager Software (RevMan) files, obtained from the Cochrane Editorial Unit, were customized to reflect the critical outcomes previously identified (outcomes not relevant to this guideline were excluded). The RevMan files were exported to the GRADE profiler software to prepare the evidence summaries according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for assessing the overall quality of the evidence

---

1 As part of the Cochrane pre-publication editorial process, reviews are commented on by external peers (an editor and two referees external to the editorial team) and the group’s statistical adviser (http://www.cochrane.org/cochrane-reviews). The Cochrane handbook for systematic reviews of interventions describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of health-care interventions.
Management of conflicts of interest

According to the rules in the WHO Basic documents (30), all experts participating in WHO meetings must declare any interest relevant to the meeting prior to their participation. The conflicts of interest statements for all guideline group members were reviewed by the responsible technical officer and the relevant departments before finalization of the group composition and invitation to attend a guideline group meeting. All guideline group members and participants of the guideline development meetings submitted a Declaration of Interests Form along with their curriculum vitae before each meeting. In addition, they verbally declared potential conflicts of interest at the beginning of each meeting. The procedures for management of conflicts of interests strictly followed the WHO Guidelines for declaration of interests (WHO experts) (31). The potential conflicts of interest declared by members of the guideline group are summarized below.

- Professor Michael Clarke declared being Director of the UK Cochrane Centre and a member of The Cochrane Collaboration. Professor Clarke was not personally involved in the preparation or management of the systematic reviews on vitamin A supplementation used for this guideline, although some of his colleagues were involved.
• Dr Jean Humphrey declared that her research unit received research grants from 1996 to 2009 for the Zimbabwe Vitamin A for Mothers and Babies Project (ZVITAMBO) from various organizations, including the Nestlé Foundation, BASF, and the Pediatric AIDS Foundation, which receives its core funds from various organizations including Johnson & Johnson and the Abbott Fund. Sub-studies were also supported by Support for Analysis and Research in Africa (SARA) and Linkages Projects, both managed by the Academy for Educational Development (AED). To our knowledge, other than BASF, none of these companies nor their commercial sponsors directly or indirectly produce vitamin A supplements.

• Dr Charles Stephensen declared receiving research funds from WHO for the conduct of a human study on the efficacy of newborn vitamin A supplementation in improving immune function and from the United States National Institutes of Health for the conduct of studies on vitamin A and immune function in mice.

• Dr Sherry Tanumihardjo declared receiving remuneration as a technical consultant for the International Atomic Energy Agency (IAEA) and an honorarium from HarvestPlus. She also received research support from: HarvestPlus for a vitamin A efficacy study in Zambian children fed orange maize and for a banana study in gerbils to determine the vitamin A value of provitamin A carotenoids; the United States National Institutes of Health for developing a 13C retinol isotope dilution test; the United States Department of Agriculture (USDA) for the use of α-retinol as a chylomicron tag in rats and pigs; and WHO for mechanistic studies to understand neonatal vitamin A supplementation using the sow-piglet dyad model. In addition, she received reimbursement for travel expenses from IAEA, HarvestPlus and WHO to attend meetings. To our knowledge, neither HarvestPlus nor its commercial sponsors directly or indirectly produce vitamin A supplements.

External resource persons were invited to the meetings as observers and to provide technical input, but they did not participate in the decision-making processes.

Plans for updating the guideline

The recommendation in this guideline will be reviewed in 2016. If new information is available at that time, a guideline review group will be convened to evaluate the new evidence and revise the recommendation. The Department of Nutrition for Health and Development at the WHO headquarters in Geneva, along with its internal partners, will be responsible for coordinating the guideline update, following the formal WHO handbook for guideline development (28) procedures. WHO welcomes suggestions regarding additional questions for evaluation in the guideline when it is due for review.


Annex 1 GRADE “Summary of findings” table

Vitamin A supplementation in infants and young children 6–59 months of age

**Patient or population:** Infants and young children 6–59 months of age  
**Settings:** Low- and middle-income countries  
**Intervention:** Vitamin A supplementation

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>RR 0.76</td>
<td>194 798 (17 studies)</td>
<td>⊕⊕⊕⊕ high</td>
<td>Inclusion of the DEVTA trial reduced the effect size. RR 0.76 (95% CI 0.69–0.83) to RR 0.88 (95% CI 0.84–0.94)</td>
</tr>
<tr>
<td>Follow-up: 12–96 weeks</td>
<td>(0.69–0.83)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All-cause mortality (HIV+ children)</strong></td>
<td>RR 0.55</td>
<td>262 (3 studies)</td>
<td>⊕⊕⊕ moderate¹</td>
<td></td>
</tr>
<tr>
<td>Hospital files or verbal autopsy forms</td>
<td>(0.37–0.82)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up: 6–24 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diarrhoea-related mortality</strong></td>
<td>RR 0.72</td>
<td>90 951 (7 studies)</td>
<td>⊕⊕⊕ moderate²</td>
<td>Total number of participants reflects number randomized to studies. The analysis combined cumulative risk and risk per/1000 years follow-up</td>
</tr>
<tr>
<td>Follow-up: 48–104 weeks</td>
<td>(0.57–0.91)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Measles-related mortality</strong></td>
<td>RR 0.80</td>
<td>88 261 (5 studies)</td>
<td>⊕⊕⊕ moderate³</td>
<td>Total number of participants reflects number randomized to studies. The analysis combined cumulative risk and risk per/1000 years follow-up</td>
</tr>
<tr>
<td>Follow-up: 52–104 weeks</td>
<td>(0.51–1.24)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lower respiratory tract infection-related mortality</strong></td>
<td>RR 0.78</td>
<td>90 951 (7 studies)</td>
<td>⊕⊕⊕⊕ low²³</td>
<td>Total number of participants reflects number randomized to studies. The analysis combined cumulative risk and risk per/1000 years follow-up</td>
</tr>
<tr>
<td>Follow-up: 48–104 weeks</td>
<td>(0.54–1.14)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; RR, risk ratio; HIV, human immunodeficiency virus.  
* GRADE Working Group grades of evidence:  
**High quality:** We are very confident that the true effect lies close to that of the estimate of the effect.  
**Moderate quality:** We have moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  
**Low quality:** Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.  
**Very low quality:** We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.  
1 Imprecision due to few deaths and small HIV+ groups in the three studies included in the meta-analysis.  
² The risk of bias assessments determined that Daulaire (1992) and Herrera (1992) were at risk of selection bias. Detection bias put the results of Daulaire (1992) at a high risk of bias. Attrition bias was considered to put the results of Chowdhury (2002) at a high risk of bias. Baseline imbalance was noted for Agarwal (1995).  
³ The wide confidence intervals around the pooled effect estimate included both a reduction and an increase in the risk of mortality with vitamin A.

For details of studies included in the review, see reference (4).  

(Continued overleaf)
### Vitamin A supplementation in infants and young children 6–59 months of age

**Patient or population:** Infants and young children 6–59 months of age  
**Settings:** Low- and middle-income countries  
**Intervention:** Vitamin A supplementation

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhoea-related hospital admission (HIV+ children)</td>
<td>RR 0.25 (0.05–1.15)</td>
<td>194 (1 study)</td>
<td>⊕⊕⊕⊝ moderate¹</td>
<td>Only one study reported on this outcome</td>
</tr>
<tr>
<td>Maternal recall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up: 6–18 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea incidence</td>
<td>RR 0.85 (95% CI 0.82–0.87)</td>
<td>69 972 (13 studies)</td>
<td>⊕⊕⊕ low¹</td>
<td></td>
</tr>
<tr>
<td>Ratio of rates of episodes per child</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up: 24–60 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute respiratory infection-related hospital admission (HIV+ children)</td>
<td>RR 0.6 (0.15–2.44)</td>
<td>194 (1 study)</td>
<td>⊕⊕⊕ moderate¹</td>
<td>Only one study reported on this outcome</td>
</tr>
<tr>
<td>Maternal recall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up: 6–18 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower respiratory tract infection-related morbidity – incidence</td>
<td>RR 1.14 (95% CI 0.95–1.37)</td>
<td>19 566 (9 studies)</td>
<td>⊕⊕⊕ very low¹</td>
<td></td>
</tr>
<tr>
<td>Mean episodes/child per year</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up: mean 52 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>RR 2.75 (1.81–4.19)</td>
<td>2994 (3 studies)</td>
<td>⊕⊕⊕ low¹</td>
<td></td>
</tr>
<tr>
<td>Follow-up: 0.14–52 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; RR, risk ratio; HIV, human immunodeficiency virus.

* GRADE Working Group grades of evidence:

- **High quality:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate quality:** We have moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low quality:** Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.
- **Very low quality:** We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.

¹ Imprecision due to wide variation in confidence intervals, which translates into wide variation in absolute effect.
² The risk of bias assessment determined that four studies contributing just over 25% weight of the estimated effect were at risk of selection or attrition bias.
³ The I² was 95%, and the results of Cheng (1993), Chowdhury (2002) and Herrera (2002) demonstrated clear evidence of benefit and were discordant with the results of the other studies.
⁴ The risk of bias assessment determined that Cheng (1993), Chowdhury (2002) and Kartasasmita (1995) were at high risk of attrition bias.
⁵ Diagnostic procedures were not consistent across the studies.
⁶ The confidence intervals around the pooled effect included small benefit and a meaningful increase in the risk of respiratory tract infections.
⁷ The follow-up was spread between 1 day and 52 weeks.
⁸ There was some evidence of underreporting of adverse events in some of the studies, and the low number of trials giving data in relation to the large number of studies included overall, means that this selective reporting of adverse events cannot be excluded.

For details of studies included in the review, see reference (4).
Annex 2

Members of the WHO/UNICEF Steering Committee for guidelines on vitamin A supplementation

**WHO**

**Dr Rajiv Bahl**  
Medical Officer  
Newborn and Child Health and Development Unit  
Department of Child and Adolescent Health and Development

**Ms Tracey Goodman**  
Technical Officer  
Expanded Programme on Immunization Plus Unit  
Department of Immunization, Vaccines and Biologicals

**Dr Matthews Mathai**  
Medical Officer  
Norms and Country Support Cooperation Unit  
Department of Making Pregnancy Safer

**Dr Mario Merialdi**  
Coordinator  
Improving Maternal and Perinatal Health Unit  
Department of Reproductive Health and Research

**Dr Juan Pablo Peña-Rosas**  
Coordinator  
Micronutrients Unit  
Department of Nutrition for Health and Development

**Dr Lisa Rogers**  
Technical Officer  
Micronutrients Unit  
Department of Nutrition for Health and Development

**UNICEF**

**Mr Arnold Timmer**  
Senior Adviser  
Micronutrients Unit  
UNICEF Nutrition Section
Annex 3

Members of the Vitamin A Supplementation Guideline Group, WHO Secretariat and external resource experts

A. Members of the Vitamin A Supplementation Guideline Group

(Note: the areas of expertise of each guideline group member are given in italics)

Professor Hany Abdel-Aleem
Assiut University Hospital
Assiut, Egypt
*Obstetrics and gynaecology*

Professor Michael Clarke
University of Oxford
Oxford, England
*Methods*

Dr Anna Coutsoudis
University of KwaZulu-Natal
Durban, South Africa
*Vitamin A, infectious disease*

Dr M. Monir Hossain
Bangladesh Institute of Child Health and Dhaka Shishu (Children) Hospital
Sher-e-Bangla Nagar
Dhaka, Bangladesh
*Neonatology*

Dr Jean Humphrey
Zimbabwe Vitamin A for Mothers and Babies Project (ZVITAMBO)
Harare, Zimbabwe
*Vitamin A, human immunodeficiency virus (HIV)*

Dr Yustina Anie Indriastuti
Indonesian Medical Doctor Nutrition Society
Jakarta, Indonesia
*Programme Manager*

Dr Marzia Lazzerini
Institute for Maternal and Child Health
Trieste, Italy
*Methods, paediatrics*

Dr Pavitra Mohan
UNICEF India Country Office
New Delhi, India
*Paediatrics*

Dr Rintaro Mori
University of Tokyo
Tokyo, Japan
*Paediatrics*

Dr A. Catherine Ross
Pennsylvania State University
University Park, United States of America
*Vitamin A, immunology*

Dr Isabella Sagoe-Moses
Ghana Health Service – Ministry of Health
Accra, Ghana
*Programme Manager*

Dr Claudia Saunders
Instituto de Nutrição Josué de Castro
Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil
*Vitamin A research programmes*

Dr Prak Sophonneary
National Maternal and Child Health Center
Ministry of Health
Phnom Penh, Cambodia
*Programme Manager*

Dr Charles Stephensen
USDA Western Human Nutrition Research Center
Davis, United States of America
*Vitamin A, immunology*

Dr Sherry Tanumihardjo
University of Wisconsin
Madison, United States of America
*Vitamin A metabolism*

Dr Khalid Yunis
American University of Beirut
Beirut, Lebanon
*Neonatology, perinatology*
B. WHO

Mr Joseph Ashong
Intern (rapporteur)
Micronutrients Unit
Department of Nutrition for Health and Development

Dr Francesco Branca
Director
Department of Nutrition for Health and Development

Ms Emily Cercone
Intern (rapporteur)
Micronutrients Unit
Department of Nutrition for Health and Development

Dr Luz Maria de Regil
Epidemiologist
Micronutrients Unit
Department of Nutrition for Health and Development

Dr Chris Duncombe
Medical Officer
Anti-retroviral Treatment and HIV Care Unit
Department of HIV/AIDS

Dr Davina Gheresi
Team Leader
International Clinical Trials Registry Platform
Department of Research Policy and Cooperation

Dr Ahmet Metin Gulmezoglu
Medical Officer
Technical Cooperation with Countries for Sexual and Reproductive Health
Department of Reproductive Health and Research

Dr Regina Kulier
Scientist
Guideline Review Committee Secretariat
Department of Research Policy and Cooperation

Dr José Martines
Coordinator
Newborn and Child Health and Development Unit
Department of Child and Adolescent Health and Development

Ms Sueko Matsumura
Intern (rapporteur)
Micronutrients Unit
Department of Nutrition for Health and Development

Dr Sant-Rayn Pasricha
Intern (rapporteur)
Micronutrients Unit
Department of Nutrition for Health and Development

C. WHO regional offices

Dr Abel Dushimimana
Medical Officer
WHO Regional Office for Africa
Brazzaville, Congo

Dr Chessa Lutter
Regional Adviser
Unit on Child and Adolescent Health
WHO Regional Office for the Americas/
Pan American Health Organization
Washington, United States of America
D. External resource experts

Dr Denise Coitinho Delmuè
United Nations System Standing Committee on Nutrition (SCN)
Geneva, Switzerland

Dr Rafael Flores-Ayala
Centers for Disease Control and Prevention (CDC)
Atlanta, United States of America

Ms Alison Greig
Micronutrient Initiative
Ottawa, Canada

Mr Toby Lasserson
Cochrane Editorial Unit
London, England

Dr Lynnette Neufeld
Micronutrient Initiative
Ottawa, Canada

Dr Mathilde Savy
Institut de Recherche pour le Développement (IRD)
Montpellier, France

Dr David Tovey
Cochrane Editorial Unit
London, England
Annex 4

Members of the External Experts and Stakeholders Panel

A. Members commenting on priority questions on vitamin A supplementation (October 2009)

**Engineer Alaa I. Abu Rub**
Ministry of Health
Palestinian National Authority
Ramallah, West Bank and Gaza Strip

**Dr Clayton Ajello**
Vitamin Angels
Santa Barbara, United States of America

**Dr Mohamed Ag Ayoya**
UNICEF, India Country Office
New Delhi, India

**Professor Hassan Aguenauou**
Ibn Tofail University
Kénitra, Morocco

**Mrs Deena Alasfoor**
Ministry of Health
Muscat, Oman

**Ms Maria Theresa Alvarez**
Academy for Educational Development (AED) – A2Z Project
Manila, Philippines

**Mr Ravi Raj Atrey**
SOS Children’s Villages of India
New Delhi, India

**Mr Shawn Baker**
Helen Keller International
Dakar-Yoff, Senegal

**Dr Christine Stabell Benn**
Bandim Health Project
Statens Serum Institut
Copenhagen, Denmark

**Dr Djibril Cissé**
Helen Keller International
Dakar-Yoff, Senegal

**Professor Pradeep Deshmukh**
Dr Sushila Nayar School of Public Health
Mahatma Gandhi Institute of Medical Sciences
Sewagram, India

**Dr Amol Dongre**
Mahatma Gandhi Institute of Medical Sciences
Sewagram, India

**Dr Masako Fujita**
Michigan State University
East Lansing, United States of America

**Dr Bishan Garg**
Dr Sushila Nayar School of Public Health
Mahatma Gandhi Institute of Medical Sciences
Sewagram, India

**Dr Ajay Gaur**
GR Medical College
Gwalior, India

**Ms Alison Greig**
Micronutrient Initiative
Ottawa, Canada

**Dr Laurence M. Grummer-Strawn**
Centers for Disease Control and Prevention (CDC)
Atlanta, United States of America

**Dr Maria Claret C.M. Hadler**
Federal University of Goiás
Goiânia, Brazil

**Dr Samia Halileh**
Institute of Community and Public Health
Birzeit University
Birzeit, West Bank and Gaza Strip
Ms Nancy J. Haselow  
Helen Keller International  
Phnom Penh, Cambodia

Dr Jocelyn A. Juguan  
Food and Nutrition Research Institute  
Department of Science and Technology  
Manila, Philippines

Dr Umesh Kapil  
All India Institute of Medical Sciences  
New Delhi, India

Dr Chen Ke  
Maternal and Children’s Health Care Hospital  
Chengdu, China

Dr Klaus Kraemer  
Sight and Life  
Basel, Switzerland

Mr Hou Kroen  
Helen Keller International  
Phnom Penh, Cambodia

Dr Anand Lakshman  
Micronutrient Initiative  
New Delhi, India

Ms Ada Lauren  
Vitamin Angels  
Santa Barbara, United States of America

Dr Tingyu Li  
Children’s Hospital of Chongqing Medical University  
Chongqing, China

Dr Georg Lietz  
Newcastle University  
Newcastle upon Tyne, England

Dr Kurt Long  
University of Queensland  
Brisbane, Australia

Dr Zeba Mahmud  
Micronutrient Initiative  
Dhaka, Bangladesh

Dr Najat Mokhtar  
Ibn Tofail University  
Kénitra, Morocco

Dr Siti Muslimatun  
Southeast Asian Ministers of Education Organization  
Tropical Medicine and Public Health Network (SEAMEO TROPMED)  
Jakarta, Indonesia

Mr Banda Ndiaye  
Micronutrient Initiative  
Dakar, Senegal

Dr Lakshmi Rahmathullah  
Family Health and Development Research Service Foundation  
Madurai, India

Professor H.P.S. Sachdev  
Maulana Azad Medical College  
New Delhi, India

Dr Tina Sanghvi  
Academy for Educational Development  
Washington, United States of America

Ms Dimple Save  
JICA-MP Reproductive Health Project  
Bhopal, India

Dr Al Sommer  
Johns Hopkins Bloomberg School of Public Health  
Baltimore, United States of America

Dr Lize van Stuijvenberg  
Medical Research Council  
Cape Town, South Africa

Dr Hans Verhoef  
London School of Hygiene and Tropical Medicine  
London, England

Dr Sheila Vir  
Public Health Nutrition and Development Centre  
New Delhi, India
B. Members commenting on the draft guideline on vitamin A supplementation (March 2011)

Dr Christine Stabell Benn
Bandim Health Project
Statens Serum Institut
Copenhagen, Denmark

Professor Hans K. Biesalski
Department of Biological Chemistry and Nutrition
Hohenheim University
Stuttgart, Germany

Ms Nita Dalmiya
UNICEF Nutrition Section
New York, United States of America

Ms Alison Greig
Micronutrient Initiative
Ottawa, Canada

Dr Roland Kupka
UNICEF Regional Office for West and Central Africa
Dakar-Yoff, Senegal

Ms Ada Lauren
Vitamin Angels Alliance
Santa Barbara, United States of America

Dr David L. Yeung
H.J. Heinz Company Foundation
Toronto, Canada

Dr Jian Zhang Yang
Columbia University
New York, United States of America

Dr Xiaoying Zheng
Institute of Population Research, Peking University
Beijing, China

Dr Teresa Murguía Peniche
National Center for Child and Adolescent Health
Mexico City, Mexico

Ms Anna Roesler
Menzies School of Health Research
Casuarina, Australia

Dr Amal Saeed
University of Khartoum
Khartoum, Sudan

Dr Martha Elizabeth van Stuijvenberg
South African Medical Research Council
Cape Town, South Africa

Dr Sheila Vir Chander
Public Health Nutrition and Development Centre
New Delhi, India

Dr Frank Wieringa
Institut de Recherche pour le Développement
Marseilles, France
Annex 5

**Effects and safety of vitamin A supplementation in infants and children 6–59 months of age**

a. Should vitamin A supplements be given to infants and children 6–59 months of age?
b. If so, at what dose and frequency?

**Questions in Population, Intervention, Control, Outcomes (PICO) format**

**Population:**
- Infants and children 6–59 months of age living in countries where vitamin A deficiency may be of public health concern
  - Subpopulations:
    - By child (under 5) mortality rates: countries with low versus high rates
    - By interaction with immunization: children receiving vitamin A around the time of measles vaccination versus other times
    - By child HIV status: HIV-positive versus HIV-negative versus mixed/unknown
    - By exposure to additional vitamin A: children who also received vitamin A supplementation during the first 28 days of life and/or at 1–5 months of age versus those who had not received vitamin A before

**Intervention:**
- Any oral vitamin A supplement
  - Subgroup analyses:
    - By dose: standard dose (100,000 IU for children 6–11 months of age and 200,000 IU for children 12–59 months of age) versus other doses
    - By frequency: every 4–6 months versus other
    - By timing: receipt of first dose at 6 months of age versus at 9-month measles contact versus other

**Control:**
- Placebo or no treatment

**Outcomes:**
- Critical
  - Mortality within the follow-up period:
    - Any cause
    - Acute respiratory infections
    - Diarrhoea
    - Measles
  - Hospitalization/clinic visits (number and duration) within the follow-up period:
    - Any cause
    - Acute respiratory infections
    - Diarrhoea
    - Adverse effects within 72 hours after receiving supplement
      - Vomiting
      - Others

**Setting:**
- All countries
Annex 6

Summary of considerations for determining the strength of the recommendation

Quality of evidence:
• Moderate quality of evidence for most critical outcomes
• Low quality of evidence for the side-effect of vomiting

Values and preferences:
• This intervention has been in place for many years now and is acceptable to most but not all
• Other options (i.e. fortification) may be preferred in order to reach a larger proportion of the target population

Trade-off between benefits and harm:
• There is benefit of reducing mortality with few side-effects
• However, one cannot rule out that in certain settings there may not be a benefit
• There is concern that those who need this intervention the most may not be reached

Costs and feasibility:
• Capsules are available at a minimal cost
• There is a moderate cost of delivering the intervention
• In the least developed countries, coverage of vitamin A supplementation is the highest, so there is evidence that these children can be reached
• Child health days are one mechanism by which countries may deliver a set of interventions to large proportion of the population (along with deworming, bed nets)
• Programmes delivering vitamin A alone (without other interventions) may be more costly
• There is a need to have a fixed place and time for distribution of this and other health interventions
• Longer-term solutions may be needed
For more information, please contact:

Department of Nutrition for Health and Development
World Health Organization
Avenue Appia 20, CH-1211 Geneva 27, Switzerland
Fax: +41 22 791 4156
E-mail: nutrition@who.int
www.who.int/nutrition